RESEARCH MONOGRAPH · KDC-MN-179

Curcumin

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

70/100

Real anti-inflammatory mechanism, terrible bioavailability, and the formulation matters more than the dose

Curcumin is the principal curcuminoid in turmeric (Curcuma longa) and one of the most-published natural compounds in biomedical research, with thousands of papers covering anti-inflammatory, antioxidant, anticancer, and metabolic effects. The mechanism breadth is genuinely impressive, with documented modulation of NF-kB, JAK/STAT, PI3K/Akt, MAPK, beta-catenin, and a dozen other signaling cascades.

The problem is that almost none of this matters at conventional oral curcumin doses because the bioavailability of unmodified curcumin is essentially zero. Plasma concentrations after 8g of oral curcumin powder peak in the nanomolar range, while the IC50s for most of the cited mechanisms are in the micromolar range. So a lot of the in vitro pharmacology that papers cite is irrelevant to oral dosing without a delivery solution.

The formulation story is where this gets interesting and where the actual clinical signal lives. Several different formulation approaches genuinely raise plasma curcumin into the relevant range. Meriva (phytosome with phosphatidylcholine, around 20-30x bioavailability improvement), BCM-95 (curcumin with turmeric oils), Theracurmin (nanocolloidal dispersion), Longvida (solid lipid particle), Cavacurmin (cyclodextrin complex), and a few others have human PK studies supporting genuine increases in plasma exposure.

With those formulations the clinical evidence is real. Multiple RCTs in osteoarthritis (effect sizes competitive with NSAIDs in some trials), modest signal in depression as an adjunct, real signal in inflammatory bowel disease at higher doses, and some interesting signal in metabolic syndrome and lipids. Effect sizes are modest but consistent.

Mechanism summary at relevant exposures is broadly anti-inflammatory, NF-kB inhibition being a useful organizing concept even if curcumin hits a lot more than that.

Sourcing here is genuinely complicated. Bulk curcumin (95% curcuminoids) at supplement prices is essentially throwaway dosing without a bioavailability enhancer. The branded formulations are expensive but corresponds to what the clinical literature actually used. Generic piperine-curcumin combinations exist but the effect is much smaller than the phytosome or nanocolloidal approaches.

Safety is generally fine, with some GI tolerability issues at higher doses, theoretical anticoagulant effects, and a real signal for liver enzyme elevations in a minority of users with certain branded formulations.

What we like: real anti-inflammatory pharmacology in the right formulation. What we dont like: most curcumin on the market is functionally inert without a bioavailability strategy, and most marketing pages dont engage with that honestly.

Evidence: 72
Mechanism: 80
Reliability: 65
Safety: 78
Sourcing: 60
Value: 60
Signal: 72
Staying power: 75

Plain-language summary Intrigue 60 / 100

Curcumin is the principal polyphenol in turmeric. It has potent anti-inflammatory effects via NF-kB inhibition. Oral bioavailability is poor; formulations like phytosomal curcumin and BCM-95 substantially improve absorption. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Turmeric polyphenol

The principal yellow polyphenol of turmeric (Curcuma longa) with broad anti-inflammatory and antioxidant activity but very poor oral bioavailability without enhancement.

Abstract

Curcumin (CAS 458-37-7; molecular formula C21H20O6; molecular weight 368.38) is the principal yellow polyphenol pigment of turmeric (Curcuma longa) rhizome. The compound has broad anti-inflammatory activity (NF-kB inhibition, cyclooxygenase modulation, JAK/STAT modulation), antioxidant activity, and modulation of multiple cancer-related pathways. The principal limitation is poor oral bioavailability: free curcumin shows less than 1 percent oral bioavailability due to extensive first-pass metabolism. Bioavailability-enhanced formulations (Meriva, Theracurmin, Longvida, BCM-95) provide 7- to 30-fold higher plasma exposure and are required for meaningful systemic effects. Doses depend on formulation; standardized 95 percent curcuminoid powder at 1 to 3 grams is typical for non-enhanced; enhanced formulations use proportionally lower doses.

Mechanism of action

Broad anti-inflammatory: NF-kB, COX, JAK/STAT inhibition. Antioxidant. Bioavailability is the principal limitation.

Reported research dose ranges

Reported research dose ranges in the literature.

References

Aggarwal BB, et al. Curcumin: the Indian solid gold. Adv Exp Med Biol 2007.

Read the full monograph

Available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-179

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Curcumin

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs